ライフサイエンスコーパス: microneedle

1 ace of the rabbit eye in vivo using a hollow microneedle.

2 re anesthetized, and IOP was measured with a microneedle.

3 cation methods e.g. lateral application of a microneedle.

4 1microl/s) by exploiting capillarity in the microneedles.

5 n of Wistar rats using NanoPass MicronJet600 microneedles.

6 eat-labile enterotoxin (dmLT) adjuvant using microneedles.

7 f thin PLGA films by stamping with blunt-tip microneedles.

8 eproducible loading of siRNA onto individual microneedles.

9 hose achieved by topical application without microneedles.

10 low, coated, dissolving and hydrogel forming microneedles.

11 egaderm, Listerine tabs, and stainless steel microneedles.

12 and similar vertical penetration depths for microneedling, AFXL, and non-AFXL (median, 125 mum).

13 In summary, quininib-HA microneedles allow for sustained release of quininib; ar

14 They were blinded to the laterality of microneedle and sham roller assignments.

15 was not significantly different between the microneedle and sham sides (0.7 and 0.4; P = .28), respe

16 was not significantly different between the microneedle and sham sides, 4.5 mm and 3.4 mm (P = .21),

17 optimized to achieve higher 5-ALA loading on microneedles and a high delivery efficiency into porcine

18 porter (luciferase/GFP) gene was coated onto microneedles and delivered to mouse footpad.

19 on conditions, two different crystal shapes, microneedles and microribbons, are grown on a clean wate

20 Microneedles and thermal ablation are currently progress

21 ) skin penetration capability of pDNA-coated microneedles, and (iv) efficient gene expression in huma

22 Polymers, lipids, scaffolds, microneedles, and other biomaterials are rapidly emergin

23 proteins could be coated onto an array of 5 microneedles, and the coated IIV was delivered into skin

24 ents were performed using pilocarpine-coated microneedles, and the rabbit pupil size was monitored af

25 pretreatment, followed by microdermabrasion, microneedling, and curettage.

26 The microneedle aperture was modified by electropolymerizing

27 arable to that achieved by the most invasive microneedle application methods e.g. lateral application

28 ms transferred into the skin following brief microneedle application promoted local transfection and

29 We describe how the microneedles are prepared and how they can be used to ap

30 Microneedles are the micrometer size devices used for th

31 Herein, we show that a simple dissolvable microneedle array (MA) delivery system preserves the imm

32 imize the side effects, we developed a novel microneedle array (MNA) that could deliver live attenuat

33 el influenza vaccine-packaged, biodegradable microneedle array (MNs), mice displayed vigorous antigen

34 drawing back 100-300 microm or vibrating the microneedle array dramatically increased infusion flow r

35 first time the ability of the solid silicon microneedle array for punching holes to deliver choleste

36 then retracted part way before infusion or a microneedle array is inserted by mechanical vibration.

37 ntestinal wall, we have developed a biphasic microneedle array that mechanically interlocks with tiss

38 loading capacity, up to 100mug of pDNA per 5-microneedle array.

39 ive insulin delivery device using a painless microneedle-array patch ("smart insulin patch") containi

40 In this study, solid metal microneedle arrays (MNs) were investigated as a system f

41 The results showed that microneedle arrays could effectively deliver siRNA to re

42 Dissolving polymeric microneedle arrays formulated to contain recombinant CN5

43 Microneedle arrays may represent a better way to deliver

44 or possible self-administration using coated microneedle arrays was investigated for skin-targeted de

45 kin vaccination using vaccine dried on solid microneedle arrays.

46 It is anticipated that the technique of microneedle-assisted drug delivery will soon become rele

47 iled overview of designs and applications of microneedle based devices that have been approved or are

48 rds investigating the safety and efficacy of microneedle based systems are ongoing.

49 overview of clinical efforts and outcome of microneedle based systems.

50 to approval and commercialization of several microneedle based/assisted products for clinical use.

51 nge 0-630mg/dl, thus significantly improving microneedle-based biosensor performance with respect to

52 m adjuvant and administered to the skin by a microneedle-based device is as efficacious as i.m. vacci

53 The resulting microneedle-based enzyme electrode displays an interfere

54 This work opens up the possibility for microneedle-based HIV vaccination strategies that, once

55 wing delivery of various doses of vaccine by microneedle-based intradermal (i.d.) delivery or intramu

56 ically potent and synergistic constituent of microneedle-based intradermal immunization technology.

57 This microneedle-based patch can sense activated thrombin and

58 A bio-responsive microneedle-based patch, integrated with a rhodamine-sta

59 col to build and use a dual force-calibrated microneedle-based setup to quantitatively analyze the mi

60 and ongoing clinical studies performed using microneedle-based technologies for cosmetic, therapeutic

61 In this work a novel self-powered microneedle-based transdermal biosensor for pain-free hi

62 roribbons twist under irradiation, while the microneedles bend.

63 ed influenza subunit vaccine coated on metal microneedles can activate both humoral and cellular arms

64 We conclude that hollow microneedles can be used for precise microinjection into

65 demonstrated for the first time that coated microneedles can deliver drugs into the eye via intrascl

66 To test the hypothesis that coated microneedles can deliver drugs into the eye via intrascl

67 Application of topical products prior to microneedling can introduce immunogenic particles into t

68 ond approach, we used force-calibrated glass microneedles coated with apCAM ligands to guide growth c

69 s into the immune-cell-rich epidermis, using microneedles coated with releasable polyelectrolyte mult

70 Microneedles coated with sodium fluorescein were then in

71 A simple, yet precise microneedle coating method permitted reproducible loadin

72 he stability of influenza vaccine during the microneedle coating process, with a focus on the role of

73 ainst CD44 also retained functionality after microneedle coating, this form of siRNA was used in subs

74 iRNA lipoplex) was less functional following microneedle coating.

75 he strategy of delivering 5-ALA using coated microneedles could be a promising approach for photodyna

76 toward the adhesion site, but the amount of microneedle deflection did.

77 e growth cone was measured by monitoring the microneedle deflection using an optical microscope.

78 study is the first to characterise pocketed microneedle delivery of a liquid formulation into human

79 sults demonstrate the promising potential of microneedle delivery of licensed influenza subunit vacci

80 ages for administration, safety and storage, microneedle delivery of M2e-flagellin fusion protein is

81 Microneedle delivery of nucleic acids, in particular pla

82 Similarly, microneedle delivery of pilocarpine caused rapid and ext

83 functional in vivo gene silencing following microneedle delivery of siRNA.

84 A clinically appropriate microneedle delivery system for BT could have a signific

85 cells to regional lymph nodes as a result of microneedle delivery to the skin might play a role in co

86 ore shown, for the first time, that a hollow microneedle device can facilitate efficient and reproduc

87 e first to explore the potential of a hollow microneedle device for the delivery and subsequent expre

88 es the potential of a liquid-loaded pocketed microneedle device to deliver botulinum toxin A into the

89 ermal vaccine was delivered using a metallic microneedle device, AdminPen.

90 ion was done using the NanoPass MicronJet600 microneedle device.

91 iour of skin due to the rapid development of microneedle devices for drug delivery applications into

92 Microneedle devices have been proposed as a minimally in

93 explore the use of minimally-invasive steel microneedle devices to effectively deliver siRNA into sk

94 Dissolvable microneedle (DMN) patches for immunization have multiple

95 Mice vaccinated with a single microneedle dose of trehalose-stabilized influenza vacci

96 afe in vivo and quininib released from these microneedles effectively inhibits angiogenesis and RVP i

97 o evaluate efficacy and pain associated with microneedle expedited PDT.

98 It also accelerates the microneedle fabrication process and reduces its dependen

99 The pDNA-coated microneedles facilitated reporter gene expression in via

100 ers that will determine stable and effective microneedle-facilitated pDNA delivery.

101 d particles injected near the limbus using a microneedle flowed circumferentially around the eye with

102 th after a single targeted injection using a microneedle for administration of a glaucoma medication

103 Clinical reports of microneedles for cosmetic applications including acne vu

104 o identify methods to effectively use hollow microneedles for drug delivery.

105 This study evaluated the potential of coated microneedles for improved dermal delivery of 5-aminolevu

106 , sequestered on the nail surface and in the microneedle-generated pores, from which the active paylo

107 higher initial amount of PPIX in the coated microneedle group, about twice the amount of PPIX was ph

108 This polymer microneedle has no dermal toxicity.

109 , in addition to percutaneous drug delivery, microneedles have been considered as an efficient techni

110 Especially, microneedles have been widely studied and developed for

111 the design, development and applications of microneedles have exponentially increased in the recent

112 Platelet-rich plasma and microneedling have been investigated recently as potenti

113 A hollow microneedle (HM) was prepared to deliver a phenylephrine

114 or BT to (i) visualise liquid loading of the microneedles, (ii) determine residence time of a liquid

115 The results demonstrate that microneedle immunization induced strong humoral as well

116 mal injury, separately generated around each microneedle in the dermis.

117 The pyramidal polymer microneedle in this study was fully released in skin in

118 The SCS was accessed using microneedles in a minimally invasive procedure.

119 Despite rapid increase in the use of microneedles in dermatology, there are few data about th

120 to 10 mum in diameter) were performed using microneedles in New Zealand white rabbits.

121 emonstrate rapid dissolution kinetics of the microneedles in skin.

122 e, HAdV5-PyMSP1(4)(2), to mice using silicon microneedles induces equivalent or enhanced antibody res

123 measurable inflammatory responses caused by microneedle insertion.

124 address this need, we inserted hollow, glass microneedles into hairless rat skin in vivo and human ca

125 eep cave formed in the basal portion of each microneedle, into which BCG powder could be packaged dir

126 d involving fluid collections using a second microneedle introduced into the cisterna magna.

127 ospheres into the supraciliary space using a microneedle is able to reduce IOP for one month as an al

128 Microneedles is the technique of drug delivery enhanceme

129 elivery of just 350mug of 5-ALA using coated microneedles led to about 3.2-fold higher PPIX formation

130 sembly and steady-state maintenance, we used microneedle manipulation of preassembled spindles in Xen

131 In this way, PCPP-coated microneedles may enable effective intradermal vaccinatio

132 Solid metal microneedles measuring 500 to 750 microm in length were

133 ed with microdermabrasion (median, 6731 AU), microneedling (median, 5609 AU), and curettage (median,

134 Therefore, microneedle-mediated immunization has potential to both

135 Microneedle-mediated intradermal delivery of beta-galact

136 s to induce a strong immune response through microneedle-mediated transcutaneous immunization may be

137 Previously, it was shown that microneedle-mediated transcutaneous immunization with pl

138 Microneedle-mediated vaccine priming and resultant induc

139 A microneedle method was used to measure IOP in knockout m

140 Polymeric microneedle (MN) arrays continue to receive growing atte

141 and evaluation of novel dissolving polymeric microneedle (MN) arrays for the facilitated delivery of

142 dermal delivery of NPs, via novel dissolving microneedle (MN) arrays has garnered interest in the pha

143 We availed of polymeric dissolving microneedle (MN) arrays laden with nano-encapsulated ant

144 delivery using bullet-shaped double-layered microneedle (MN) arrays with water-swellable tips.

145 We therefore sought to develop a dry-coated microneedle (MN) delivery system and combine it with top

146 This study developed a minimally-invasive microneedle (MN) patch for skin vaccination with virus-l

147 eliver the DNA to the nucleus of cells ii) a microneedle (MN) patch that will house the nanoparticles

148 art exendin-4 (Ex4) delivery device based on microneedle (MN)-array patches integrated with dual mine

149 An innovative microneedle (MN)-based cell therapy is developed for glu

150 In the present study, we demonstrate a microneedle (MN)-based cutaneous preventive allergy trea

151 ed A/California/04/09 virus via coated metal microneedles (MN) applied to skin or via subcutaneous in

152 We developed dissolving polymeric microneedles (MN) arrays to deliver GEN transdermally.

153 Microneedles (MNs) allow transdermal delivery of otherwi

154 combination of skin barrier impairment using microneedles (MNs) coupled with iontophoresis (ITP) may

155 Microneedles (MNs) effectively circumvent the skin barri

156 Microneedles (MNs) have been investigated as a minimally

157 Micrometer-scale microneedles (MNs) have been used to pierce animal and h

158 Microneedles (MNs) selectively and painlessly permeabili

159 perty of 15d-PGJ2 cream can be enhanced with microneedles (MNs).

160 niquely, heterogeneous arrays, consisting of microneedles of diverse composition, can be easily produ

161 oscopy established that coatings of 5-ALA on microneedles of the patch were uniform.

162 g factor 1 (CSF-1) stimulate collection into microneedles of tumor cells and macrophages even though

163 Recently-introduced biocompatible polymeric microneedles offer an efficient method for drug delivery

164 Biodegradable microneedles offer particular advantages however process

165 ection into the suprachoroidal space using a microneedle offers a simple and minimally invasive way t

166 By coupling the microneedles operating under capillary-action with an en

167 ed in participants who self-administered the microneedle patch (all p>0.05).

168 The biodegradable microneedle patch (MNP) is a novel technology for vaccin

169 In this study, we developed a dissolving microneedle patch (MNP) made of polyvinylpyrrolidone, du

170 an titres were similar at day 28 between the microneedle patch administered by a health-care worker v

171 41 [82%] of 50 [69-91]) after vaccination by microneedle patch application.

172 suggest that vaccination of the skin using a microneedle patch can improve protective efficacy and in

173 Immunization using a microneedle patch coated with vaccine offers the promise

174 ten-fold lower vaccine dose administered by microneedle patch generated a weaker immune response com

175 haemagglutinin per B vaccine strain) (1) by microneedle patch or (2) by intramuscular injection, or

176 (vaccine via health-care worker administered microneedle patch or intramuscular injection, or self-ad

177 dose of (4) inactivated influenza vaccine by microneedle patch self-administered by study participant

178 he first-in-man study on single, dissolvable microneedle patch vaccination against influenza.

179 es were significantly higher at day 28 after microneedle patch vaccination compared with placebo (all

180 and assess the safety and immunogenicity of microneedle patch vaccination using a rabies DNA vaccine

181 asked to the type of vaccination method (ie, microneedle patch vs intramuscular injection).

182 ntramuscular injection, or self-administered microneedle patch), overall incidence of solicited adver

183 scular injection, or received (3) placebo by microneedle patch, all administered by an unmasked healt

184 e skin using a vaccine formulated as a solid microneedle patch, confers protection superior to that w

185 rage for at least 3weeks at 4 degrees C in a microneedle patch.

186 Skin immunization with microneedle patches (MN) is a novel and safe vaccination

187 Microneedle patches are designed to serve this need by c

188 These microneedle patches can be easily and painlessly applied

189 These results suggest that dissolving microneedle patches can provide a new technology for sim

190 Microneedle patches containing 57 microneedles were coat

191 As a possible solution, microneedle patches containing an array of micron-sized

192 icity of biological sample acquisition using microneedle patches coupled with the simplicity of analy

193 l methods to collect biomarker analytes from microneedle patches for analysis by integration into con

194 Here we introduce dissolving microneedle patches for influenza vaccination using a si

195 INTERPRETATION: Use of dissolvable microneedle patches for influenza vaccination was well t

196 Here, we propose the use of dissolving microneedle patches for simple and potentially cost-effe

197 lations into the dermis using antigen-coated microneedle patches is a promising and safe approach bec

198 We conclude that dissolving microneedle patches may provide an innovative approach t

199 We conclude that microneedle patches offer a powerful new technology that

200 ping countries and discusses advantages that microneedle patches offer for vaccination to address the

201 Microneedle patches provide an alternative to convention

202 ccine formulations, which can be coated onto microneedle patches suitable for simple administration,

203 Microneedle patches were at least as immunogenic as intr

204 In another method, microneedle patches were attached to form the bottom of

205 Microneedle patches were made out of cross-linked hydrog

206 Microneedle patches were shown to swell with water up to

207 Microneedle patches were well tolerated in the skin, wit

208 ws for easy self-administration, we prepared microneedle patches with stabilized influenza vaccine an

209 To collect analytes from microneedle patches, the patches were mounted within the

210 development of point-of-care diagnostics and microneedle patches, will facilitate progress towards me

211 delivery of inactivated influenza virus with microneedle patches.

212 th the simplicity of analyte collection from microneedles patches integrated into conventional analyt

213 and non-swellable polystyrene core, conical microneedles penetrate tissue with minimal insertion for

214 emitted in vivo to micropig skin at varying microneedle penetration depths, signal amplitudes, and c

215 ation depth and area of the breach caused by microneedle penetration following staining and optical i

216 The MNs with 5 monument-shaped microneedles per array were produced and coated with ina

217 ate the importance of subcutaneous tissue on microneedle performance and the need for representative

218 imentation studies that are used to evaluate microneedle performance do not consider the biomechanica

219 The Microneedle Photodynamic Therapy II (MNPDT-II) study was

220 his study progresses the translation of this microneedle platform to eventual clinical deployment.

221 s and an associated lipophilic 'active' in a microneedle-porated nail.

222 Furthermore, with use of coated microneedles, PPIX was observed in deeper regions of the

223 0-minute incubation arm AK clearance for the microneedle pretreated side was 43% compared with 38% on

224 Photodynamic therapy with microneedle pretreatment at a 20-minute ALA incubation t

225 y outcome was to assess pain associated with microneedle pretreatment.

226 Significantly, the animals that received a microneedle prime and intranasal boost regimen elicited

227 While the microneedle primed groups demonstrated a balanced Th1/Th

228 e (IOP) was measured by using an established microneedle procedure.

229 Trailing-edge detachment and pulling with a microneedle produced motion and deformation of the nucle

230 rofluidic, drop dispensing-based dissolvable microneedle production method that overcomes these issue

231 Started from the development of simple solid microneedles, providing microporation of stratum corneum

232 The use of coated metal microneedles represents a new, simple, minimally-invasiv

233 perianal skin with minimal pain using hollow microneedles, resulting in the increase of resting anal

234 incubation times, after pretreatment with a microneedle roller (200 um) vs a sham roller.

235 esent work describes an attractive skin-worn microneedle sensing device for the minimally invasive el

236 Our results reveal that the new microneedle sensor holds considerable promise for contin

237 sertion of the MNA into the skin, individual microneedle shafts melted away by interstitial fluid fro

238 Treating the ear with microneedles showed permeation of siRNA in the skin and

239 In vivo delivery from fluorescein-coated microneedles showed that fluorescein concentrations in t

240 ys demonstrated quininib released from these microneedles significantly (p<0.0001) inhibited ocular d

241 device consists of an assembly of pyramidal microneedle structures integrated with Pt and Ag wires,

242 th a lower dose of just 1.75mg 5-ALA, coated microneedles suppressed the growth of subcutaneous tumor

243 Following recovery from the microneedle surface, lamin A/C siRNA retained full activ

244 e include (i) high dose-loading of pDNA onto microneedle surfaces, (ii) stability and functionality o

245 Using this novel microneedle system we successfully primed antigen-specif

246 One method, the use of dissolving microneedle technologies, has the potential to achieve t

247 d the need for representative skin models in microneedle technology development.

248 demonstrate that skin vaccine delivery using microneedle technology induces mobilization of long live

249 Microneedle technology provides the opportunity for the

250 ular levels, using biomechanics and magnetic microneedle technology, and show for the first time that

251 vascular smooth muscle cells using magnetic microneedle technology.

252 es use of an array of silicon-dioxide hollow microneedles that are about one order of magnitude both

253 midity, glucose and pH sensors and polymeric microneedles that can be thermally activated to deliver

254 open [corrected] facial granulomas following microneedle therapy for skin rejuvenation.

255 Microneedle therapy includes skin puncture with multiple

256 Because the microneedle therapy system is accessible for home use, h

257 izer (Vita C Serum; Sanitas Skincare) during microneedle therapy.

258 kin's barrier layer of stratum corneum using microneedles, thermal ablation, microdermabrasion, elect

259 Microneedle tips inserted into a spindle just outside th

260 lly interlocks with tissue through swellable microneedle tips, achieving ~3.5-fold increase in adhesi

261 We tested this hypothesis using microneedles to skewer metaphase spindles in Xenopus lae

262 to apply dense polymethylmethacrylate (PMMA) microneedles to the skin models in a controlled and repe

263 s, various cosmeceuticals are applied before microneedling to enhance the therapeutic effects.

264 irs for sustained topical drug delivery into microneedle-treated human nail.

265 EPD is based on ablative fractional laser or microneedle treatment of the skin to generate microchann

266 sweat can pass through an array of flexible microneedle type of sensors (50microm diameter) incorpor

267 Different microneedle types and application methods have been inve

268 The tranexamic acid biocompatible polymer microneedle used in this study was fabricated from PVP a

269 1x10(6)needles/cm(2)) than state-of-the-art microneedles used for biosensing so far.

270 Microneedle vaccination generated robust antibody and ce

271 The stabilized microneedle vaccination group showed IgG2a levels that w

272 Microneedle vaccination of mice in the skin with a singl

273 red to conventional intramuscular injection, microneedle vaccination resulted in more efficient lung

274 tional intramuscular vaccination, stabilized microneedle vaccination was superior in inducing protect

275 ymosan can be used as an immunostimulant for microneedle vaccination.

276 nificant need to find some adjuvants for the microneedle vaccination.

277 because mice vaccinated with an unstabilized microneedle vaccine elicited a weaker immunoglobulin G 2

278 ibody response, compared with the stabilized microneedle vaccine, and were only partially protected a

279 The biocompatible polymer microneedle was fabricated at 60 degrees C.

280 tration of these microspheres using a hollow microneedle was performed in the eye of New Zealand Whit

281 Quininib incorporation into these microneedles was 90%.

282 Protective efficacy with microneedles was found to be significantly better than t

283 The stability of M2e5x VLP-coated microneedles was maintained for 8weeks at room temperatu

284 ofile of quininib released in vitro from the microneedles was quantified by HPLC.

285 An array of five stainless steel pocketed microneedles was shown to possess sufficient capacity to

286 Delivery of TA to the SCS using microneedles was simple, effective, and not associated w

287 Coated microneedles were able to reproducibly perforate human s

288 Microneedle patches containing 57 microneedles were coated with 5-ALA using an in-house de

289 HA activity of influenza VLP vaccines after microneedles were coated.

290 imonidine at a constant rate for 35 days and microneedles were designed to penetrate through the scle

291 Microneedles were fabricated using a biocompatible polym

292 Quininib-HA microneedles were formulated via desolvation from quinin

293 In vitro insertion tests showed that microneedles were mechanically strong enough to penetrat

294 d DNA onto a skin area pretreated with solid microneedles were significantly enhanced by coating the

295 directly correlated to the stiffness of the microneedle, which is consistent with a reinforcement me

296 quininib was formulated into hyaluronan (HA) microneedles whose safety and efficacy was evaluated in

297 he efficiency of gene expression from coated microneedles will depend upon suitable DNA loading, effi

298 es cerevisiae, or poly (I:C) was coated on a microneedle with inactivated influenza virus, and then i

299 Coating of microneedles with influenza VLPs using an unstabilized f

300 ttage, microdermabrasion with abrasive pads, microneedling with dermarollers, ablative fractional las